Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2644)	10/16/2009 3:04:06 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

BASI is still up 75.49% on volume of > 156,270 about 40x its ADV The stock is having a good spike. It traded at the highest level so far this Yr. bigcharts.marketwatch.com BASI is trying to get off from the longer term DT coming from its Dec 2007 H of $9.39 The July 2001 H was $14.50 bigcharts.marketwatch.com The stock had been trading around 0.3xBV with +CF around $0.70 BASI provides contract development services and research equipment to pharmaceutical, medical research, and biotechnology companies worldwide. It operates in two segments, Research Services and Research Products. The Research Services provides various services, including screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets robotic sampling systems, including disposables, training, and systems qualification; in vivo microdialysis collection systems; physiology monitoring tools; and liquid chromatography and electrochemistry instrument platforms. Its product portfolio includes a robotic automated pharmacology system; bioanalytical separation systems to detect and quantify low concentrations of substances; specialized chemical analyzers that monitor trace levels of organic chemicals; epsilon, a single liquid chromatography and electrochemistry instrument control platform; a line of miniaturized in vivo sampling devices sold to drug developers and medical research centers that assist in the study of various medical conditions including stroke, depression, Alzheimer's and Parkinson's diseases, diabetes, and osteoporosis; and Vetronics, animal diagnostic electro-cardiogram and vital signs monitors used in veterinary clinics. It also also manufactures scientific instruments for medical research, which it sells with related software for use in industrial, governmental, and academic laboratories. Bernard

To: Jibacoa who wrote (2644)	6/11/2010 12:45:51 PM
From: Jibacoa	Respond to of 3722

MDNU opened today with another UG, much larger than yesterday's. <g> Volume of > 527Ks is about 118x its ADV. <g> bigcharts.marketwatch.com MDNU announced today that it has entered into a merger agreement with Danone, under which Danone will acquire all the outstanding shares of MDNU for $4.00 per share in cash, in a transaction valued at approximately $62.3M The $4 level is where MDNU has a good amount of resistance, but < half the ACTAY of $8.25 <g> bigcharts.marketwatch.com And of course, some good intentioned lawyers are already coming out in defense of the poor stockholders, alleging that Danone is underpaying for MDNU shares.<g> finance.yahoo.com Bernard